138 related articles for article (PubMed ID: 25885521)
21. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
[TBL] [Abstract][Full Text] [Related]
22. VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis.
Genovese MC; van Vollenhoven RF; Pacheco-Tena C; Zhang Y; Kinnman N
Arthritis Rheumatol; 2016 Jan; 68(1):46-55. PubMed ID: 26473751
[TBL] [Abstract][Full Text] [Related]
23. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies.
Damjanov N; Kauffman RS; Spencer-Green GT
Arthritis Rheum; 2009 May; 60(5):1232-41. PubMed ID: 19404957
[TBL] [Abstract][Full Text] [Related]
24. OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy.
Taylor PC; Genovese MC; Greenwood M; Ho M; Nasonov E; Oemar B; Stoilov R; Vencovsky J; Weinblatt M
Ann Rheum Dis; 2015 Dec; 74(12):2123-9. PubMed ID: 25074688
[TBL] [Abstract][Full Text] [Related]
25. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
26. Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.
Genovese MC; Hsia E; Belkowski SM; Chien C; Masterson T; Thurmond RL; Manthey CL; Yan XD; Ge T; Franks C; Greenspan A
J Rheumatol; 2015 Oct; 42(10):1752-60. PubMed ID: 26233509
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial.
Nuki G; Bresnihan B; Bear MB; McCabe D;
Arthritis Rheum; 2002 Nov; 46(11):2838-46. PubMed ID: 12428223
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study.
Furst DE; Saag K; Fleischmann MR; Sherrer Y; Block JA; Schnitzer T; Rutstein J; Baldassare A; Kaine J; Calabrese L; Dietz F; Sack M; Senter RG; Wiesenhutter C; Schiff M; Stein CM; Satoi Y; Matsumoto A; Caldwell J; Harris RE; Moreland LW; Hurd E; Yocum D; Stamler DA
Arthritis Rheum; 2002 Aug; 46(8):2020-8. PubMed ID: 12209503
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.
Stohl W; Merrill JT; McKay JD; Lisse JR; Zhong ZJ; Freimuth WW; Genovese MC
J Rheumatol; 2013 May; 40(5):579-89. PubMed ID: 23547209
[TBL] [Abstract][Full Text] [Related]
30. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study.
Vergunst CE; Gerlag DM; von Moltke L; Karol M; Wyant T; Chi X; Matzkin E; Leach T; Tak PP
Arthritis Rheum; 2009 Dec; 60(12):3572-81. PubMed ID: 19950299
[TBL] [Abstract][Full Text] [Related]
31. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate.
Genovese MC; Lee E; Satterwhite J; Veenhuizen M; Disch D; Berclaz PY; Myers S; Sides G; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1453-60. PubMed ID: 23599435
[TBL] [Abstract][Full Text] [Related]
32. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine.
Keystone EC; Wang MM; Layton M; Hollis S; McInnes IB;
Ann Rheum Dis; 2012 Oct; 71(10):1630-5. PubMed ID: 22966146
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate.
Stock TC; Bloom BJ; Wei N; Ishaq S; Park W; Wang X; Gupta P; Mebus CA
J Rheumatol; 2012 Apr; 39(4):720-7. PubMed ID: 22382341
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
Braun J; Kästner P; Flaxenberg P; Währisch J; Hanke P; Demary W; von Hinüber U; Rockwitz K; Heitz W; Pichlmeier U; Guimbal-Schmolck C; Brandt A;
Arthritis Rheum; 2008 Jan; 58(1):73-81. PubMed ID: 18163521
[TBL] [Abstract][Full Text] [Related]
35. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Mazurov V; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Mpofu S
Ann Rheum Dis; 2013 Jun; 72(6):863-9. PubMed ID: 22730366
[TBL] [Abstract][Full Text] [Related]
37. Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients.
Smolen JS; van Vollenhoven R; Kavanaugh A; Strand V; Vencovsky J; Schiff M; Landewé R; Haraoui B; Arendt C; Mountian I; Carter D; van der Heijde D
Arthritis Res Ther; 2015 Sep; 17(1):245. PubMed ID: 26353833
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of a selective estrogen receptor β agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study.
Roman-Blas JA; Castañeda S; Cutolo M; Herrero-Beaumont G
Arthritis Care Res (Hoboken); 2010 Nov; 62(11):1588-93. PubMed ID: 20556817
[TBL] [Abstract][Full Text] [Related]
39. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.
Fleischmann R; Cutolo M; Genovese MC; Lee EB; Kanik KS; Sadis S; Connell CA; Gruben D; Krishnaswami S; Wallenstein G; Wilkinson BE; Zwillich SH
Arthritis Rheum; 2012 Mar; 64(3):617-29. PubMed ID: 21952978
[TBL] [Abstract][Full Text] [Related]
40. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.
Smolen JS; Beaulieu A; Rubbert-Roth A; Ramos-Remus C; Rovensky J; Alecock E; Woodworth T; Alten R;
Lancet; 2008 Mar; 371(9617):987-97. PubMed ID: 18358926
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
